Halozyme Therapeutics (HALO) Amortization of Deferred Charges (2012 - 2018)

Halozyme Therapeutics (HALO) has 7 years of Amortization of Deferred Charges data on file, last reported at -$455000.0 in Q4 2018.

• On a quarterly basis, Amortization of Deferred Charges rose 26.26% year-over-year to -$455000.0 in Q4 2018; TTM through Dec 2018 was $1.5 million, a 12.27% decrease from a year earlier, with the FY2018 full-year figure at $1.5 million, down 12.27% from the prior year.
• Amortization of Deferred Charges for Q4 2018 stood at -$455000.0, down from $303000.0 in the prior quarter.
• Over the last five years, Amortization of Deferred Charges for HALO reached as high as $1.5 million in Q1 2017 and fell as low as -$617000.0 in Q4 2017.
• Historically, Amortization of Deferred Charges has averaged $473500.0 across 5 years, with a median of $432000.0 in 2014.
• Across the five-year window, Amortization of Deferred Charges jumped 512.79% in 2016 and sank 236.5% in 2017, its largest moves.
• Year by year, Amortization of Deferred Charges stood at $415000.0 in 2014, then dropped by 13.73% to $358000.0 in 2015, then grew by 26.26% to $452000.0 in 2016, then sank by 236.5% to -$617000.0 in 2017, then grew by 26.26% to -$455000.0 in 2018.
• Per Business Quant data, the three most recent Amortization of Deferred Charges figures were -$455000.0 in Q4 2018, $303000.0 in Q3 2018, and $345000.0 in Q2 2018.